Aytu BioPharma, Inc. (AYTU)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Joshua R. Disbrow | CEO & Director | 873.2k | -- | 1975 |
Mr. Jarrett T. Disbrow Ph.D. | Chief Business Officer | 531.09k | -- | 1975 |
Mr. Greg Pyszczymuka | Chief Commercial Officer | 505.3k | -- | 1980 |
Mr. Ryan J. Selhorn CPA | CFO, Corporate Secretary & Treasurer | -- | -- | 1982 |
Ms. Margaret Cabano | Vice President of Operations | -- | -- | -- |
Aytu BioPharma, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 102
Description
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Corporate Governance
Upcoming Events
May 13, 2025 at 8:00 PM UTC - May 19, 2025 at 8:00 PM UTC
Aytu BioPharma, Inc. Earnings Date
Recent Events
October 7, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission